[AKAO] Achaogen, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 13.01 Change: -0.14 (-1.06%)
Ext. hours: Change: 0 (0%)

chart AKAO

Refresh chart

Strongest Trends Summary For AKAO

AKAO is in the long-term down -94% below S&P in 3 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Achaogen, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antibacterials to treat multi-drug resistant gram-negative infections. The company is principally developing plazomicin, which has completed Phase II clinical trials for the treatment of bacterial infections due to multi-drug resistant Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae. It is also involved in the research and development of antipseudomonal programs that target infections caused by Pseudomonas aeruginosa. Achaogen, Inc. was incorporated in 2002 and is headquartered in South San Francisco, California.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-3.25 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -6.21% Sales Growth - Q/Q14.58% P/E-6.64
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-33.9% ROE-38.13% ROI
Current Ratio9.1 Quick Ratio Long Term Debt/Equity Debt Ratio0.12
Gross Margin Operating Margin-120.78% Net Profit Margin-121.41% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities760 K Cash From Investing Activities5.92 M Cash From Operating Activities-2.64 M Gross Profit
Net Profit-6.18 M Operating Profit-6.23 M Total Assets67.55 M Total Current Assets66.72 M
Total Current Liabilities7.33 M Total Debt Total Liabilities7.49 M Total Revenue4.88 M
Technical Data
High 52 week14.7 Low 52 week1.18 Last close1.33 Last change-4.32%
RSI50.75 Average true range0.2 Beta0.95 Volume989.56 K
Simple moving average 20 days-2.72% Simple moving average 50 days-23.37% Simple moving average 200 days-82.9%
Performance Data
Performance Week-2.56% Performance Month-17.9% Performance Quart-64.53% Performance Half-89.84%
Performance Year-90.45% Performance Year-to-date8.13% Volatility daily9.88% Volatility weekly22.09%
Volatility monthly45.27% Volatility yearly156.83% Relative Volume34.39% Average Volume1.05 M
New High New Low

News

2019-04-26 10:30:02 | Achaogen AKAO May Report Negative Earnings: Know the Trend Ahead of Q1 Release

2019-04-20 22:03:53 | We ignore the disaster in the antibiotics market at our peril

2019-04-16 19:17:11 | Achaogen AKAO Files for Bankruptcy, Shares Plunge 65%

2019-04-15 12:33:41 | Achaogen's Bankruptcy Filing, Proposed Sale: What You Need to Know

2019-04-15 07:48:22 | Achaogen Plans for Near-Term Sale Using Structured Process Through Chapter 11 of the U.S. Bankruptcy Code

2019-04-09 09:00:01 | Achaogen AKAO Upgraded to Buy: Here's Why

2019-04-01 17:48:22 | Achaogen Inc AKAO Files 10-K for the Fiscal Year Ended on December 31, 2018

2019-03-29 08:07:29 | Edited Transcript of AKAO earnings conference call or presentation 28-Mar-19 8:30pm GMT

2019-03-28 16:24:35 | Achaogen: 4Q Earnings Snapshot

2019-03-28 16:01:00 | Achaogen Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

2019-03-28 07:54:59 | The Daily Biotech Pulse: Blueprint Medicine Expedites Clinical Programs, Eyepoint Offering, Precision Biosciences IPO

2019-03-13 16:01:00 | Achaogen to Host Conference Call and Webcast of Fourth Quarter and Year 2018 Financial Results on March 28, 2019

2019-02-21 11:50:32 | Does Achaogen, Inc. NASDAQ:AKAO Have A High Beta?

2019-02-21 08:00:00 | Achaogen Announces ZEMDRI® plazomicin Pivotal Phase 3 Study Results Published in the New England Journal of Medicine

2019-02-21 08:00:00 | Achaogen Announces Publication of Plazomicin Phase 3 CARE Study Results in the New England Journal of Medicine

2019-02-20 16:02:00 | Achaogen Announces Closing of $15 Million Underwritten Public Offering

2019-02-20 16:01:00 | Achaogen Announces Presentations at Two Upcoming Investor Healthcare Conferences

2019-02-15 06:11:05 | Achaogen Announces Pricing of $15 Million Underwritten Public Offering

2019-02-14 16:00:00 | Achaogen Announces Proposed Public Offering of Common Stock

2019-02-14 08:30:00 | Achaogen Provides Update on Corporate Progress and Key Preliminary Fourth Quarter 2018 Results

2019-02-14 08:30:00 | Achaogen Submits Response to ASPR/BARDA Request for Information RFI for Antimicrobial Resistance Project BioShield

2019-01-30 23:45:02 | Why are deep-pocketed biotechs cutting hundreds of jobs?

2018-12-21 11:54:24 | Could Achaogen, Inc.’s NASDAQ:AKAO Investor Composition Influence The Stock Price?

2018-12-11 06:50:00 | Today's Research Reports on Trending Tickers: Achaogen and Arcadia Biosciences

2018-12-10 08:01:00 | Achaogen Announces FDA Clearance and Launch of the Thermo Scientific QMS Plazomicin Immunoassay

2018-12-06 07:50:00 | Recent Analysis Shows Best Buy Co., News Corporation, Semtech, Achaogen, Infosys, and Galapagos NV Market Influences — Renewed Outlook, Key Drivers of Growth

2018-11-26 10:04:07 | Health Care Digest: Genentech's blood cancer win, a boost for Gilead's HIV PrEP and a tiny IPO swings at antibiotics

2018-11-26 08:01:00 | Achaogen Announces Multiple Plazomicin Presentations at the American Society of Health Systems Pharmacists ASHP Midyear Clinical Meeting

2018-11-09 08:01:00 | Achaogen Announces Presentations at Two Investor Healthcare Conferences in November

2018-11-08 17:17:15 | Edited Transcript of AKAO earnings conference call or presentation 8-Nov-18 1:30pm GMT

2018-11-08 09:15:02 | Achaogen AKAO Reports Q3 Loss, Misses Revenue Estimates

2018-11-08 08:10:48 | Achaogen: 3Q Earnings Snapshot

2018-11-08 08:01:00 | Achaogen Reports Third Quarter 2018 Financial Results and Provides Corporate Update

2018-11-05 17:16:21 | 4 months after drug approval, Achaogen eyes fire sale

2018-11-05 09:01:00 | Achaogen Announces Review of Strategic Alternatives and Corporate Restructuring

2018-11-02 08:01:00 | Achaogen to Host Conference Call and Webcast of Third Quarter 2018 Financial Results on November 8, 2018

2018-10-29 08:55:00 | Consolidated Research: 2018 Summary Expectations for Insys Therapeutics, Achaogen, Astec Industries, Central European Media Enterprises, Pzena Investment Management, and Clementia Pharmaceuticals — Fundamental Analysis, Key Performance Indications

2018-10-17 08:01:00 | Achaogen Submits Marketing Authorization Application to the European Medicines Agency for Plazomicin

2018-10-03 08:01:00 | Achaogen Highlights Multiple Plazomicin Presentations at IDWeek 2018

2018-09-19 08:01:00 | Achaogen Announces Multiple Plazomicin Presentations at IDWeek 2018

2018-09-18 08:01:00 | Achaogen to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference

2018-09-04 04:00:00 | Achaogen Highlights Multiple Plazomicin Presentations at ESCMID/ASM 2018 Conference

2018-08-24 08:39:12 | Is the Options Market Predicting a Spike in Achaogen AKAO Stock?

2018-08-16 19:40:26 | Edited Transcript of AKAO earnings conference call or presentation 6-Aug-18 8:30pm GMT

2018-08-15 07:30:00 | Analysis: Positioning to Benefit within Northeast, Hurco Companies, PGT, Bassett Furniture Industries, Insys Therapeutics, and Achaogen — Research Highlights Growth, Revenue, and Consolidated Results

2018-08-13 16:01:00 | Achaogen to Present at the Wedbush PacGrow Healthcare Conference

2018-08-07 17:45:55 | [$$] Drug Company Achaogen Expresses Doubt About Its Viability

2018-08-07 07:13:11 | New Strong Sell Stocks for August 7th

2018-08-06 18:10:10 | Achaogen AKAO Reports Q2 Loss, Tops Revenue Estimates

2018-08-06 17:04:23 | Achaogen: 2Q Earnings Snapshot